A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G
暂无分享,去创建一个
M. Carta | A. Perra | S. Giglio | I. Piras | S. Tranquilli | D. Firinu | R. Littera | L. Lecca | M. Melis | L. Chessa | Federica Cannas | C. Ottelio | Selene Cipri | Francesca Sedda | Michela Miglianti | S. Mocci | Alessia Mascia | S. Lai | E. Giuressi | Marcello Campagna | Monica Vacca | S. Rassu | D. Schirru | Celeste Sanna
[1] T. Lancet. The COVID-19 pandemic in 2023: far from over , 2023, The Lancet.
[2] B. Chen,et al. Human genetic basis of severe or critical illness in COVID-19 , 2022, Frontiers in Cellular and Infection Microbiology.
[3] Yaolong Chen,et al. Clinical manifestations of COVID‐19: An overview of 102 systematic reviews with evidence mapping , 2022, Journal of evidence-based medicine.
[4] N. Chitnis,et al. Modelling the impact of Omicron and emerging variants on SARS-CoV-2 transmission and public health burden , 2022, Communications Medicine.
[5] Iman A. Mohammed,et al. Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries , 2022, Nature Genetics.
[6] C. Maldonado-Bernal,et al. Natural killer cell exhaustion in SARS-CoV-2 infection , 2022, Innate immunity.
[7] Fei Shao,et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.
[8] M. Mohammadnia-Afrouzi,et al. The association of decreased HLA-G+ immune cell frequencies with critical COVID-19 patients , 2022, Microbial Pathogenesis.
[9] A. Wilder-Smith,et al. Does the World Still Need New Covid-19 Vaccines? , 2022, The New England journal of medicine.
[10] A. Iolascon,et al. Germline rare variants of lectin pathway genes predispose to asymptomatic SARS-CoV-2 infection in elderly individuals , 2022, Genetics in Medicine.
[11] A. Perra,et al. A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population , 2022, Frontiers in Immunology.
[12] J. Granados,et al. Protective HLA alleles against severe COVID-19: HLA-A*68 as an ancestral protection allele in Tapachula-Chiapas, Mexico , 2022, Clinical Immunology.
[13] Madhavrao D. Chavan,et al. Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review , 2022, Journal of medical virology.
[14] A. Ad’hiah,et al. HLA-G 14-bp insertion/deletion polymorphism and risk of coronavirus disease 2019 (COVID-19) among Iraqi patients , 2022, Human Immunology.
[15] H. Zeberg. The major genetic risk factor for severe COVID-19 is associated with protection against HIV , 2022, Proceedings of the National Academy of Sciences of the United States of America.
[16] B. Seliger,et al. Role of HLA-G in Viral Infections , 2022, Frontiers in Immunology.
[17] Q. Ye,et al. The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant , 2022, Journal of medical virology.
[18] Mark S. Anderson,et al. Human genetic and immunological determinants of critical COVID-19 pneumonia , 2022, Nature.
[19] Xiao Chen,et al. Impact of vaccination on the COVID-19 pandemic in U.S. states , 2022, Scientific Reports.
[20] Wenzhong Liu,et al. COVID-19: Attacks the 1-beta Chain of Hemoglobin to Disrupt Respiratory Function and Escape Immunity , 2022 .
[21] Theodore G. Drivas,et al. Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19 , 2022, Nature Genetics.
[22] D. Singh,et al. SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines , 2021, Frontiers in Cellular and Infection Microbiology.
[23] A. Lin,et al. Perspective of HLA-G Induced Immunosuppression in SARS-CoV-2 Infection , 2021, Frontiers in Immunology.
[24] A. Hajeer,et al. Association of KIR gene polymorphisms with COVID-19 disease , 2021, Clinical Immunology.
[25] Marek J. Łos,et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment , 2021, Drug Resistance Updates.
[26] A. Bjourson,et al. Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease , 2021, Cells.
[27] Q. Ye,et al. The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape , 2021, Journal of medical virology.
[28] J. Todd,et al. Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus , 2021, Nature Genetics.
[29] R. Rizzo,et al. Increased sHLA-G Is Associated with Improved COVID-19 Outcome and Reduced Neutrophil Adhesion , 2021, Viruses.
[30] T. Fiolet,et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review , 2021, Clinical Microbiology and Infection.
[31] A. Ad’hiah,et al. Soluble HLA-G is upregulated in serum of patients with severe COVID-19 , 2021, Human Immunology.
[32] S. Pääbo,et al. A genomic region associated with protection against severe COVID-19 is inherited from Neandertals , 2021, Proceedings of the National Academy of Sciences.
[33] Dingtao Hu,et al. Influence of age and gender on the epidemic of COVID-19 , 2021, Wiener klinische Wochenschrift.
[34] Q. Lu,et al. COVID-19 and autoimmune diseases , 2020, Current opinion in rheumatology.
[35] F. Meloni,et al. Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience , 2020, Frontiers in Immunology.
[36] Q. Ye,et al. Kidney involvement in COVID‐19 and its treatments , 2020, Journal of medical virology.
[37] P. Kuppen,et al. The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy? , 2020, International journal of molecular sciences.
[38] E. Wolf,et al. Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada , 2020, Infection.
[39] T. Aw,et al. A Southeast Asian Perspective on the COVID-19 Pandemic: Hemoglobin E (HbE)-Trait Confers Resistance Against COVID-19 , 2020, Medical science monitor basic research.
[40] A. Arnaiz-Villena,et al. HLA‐G: Function, polymorphisms and pathology , 2020, International journal of immunogenetics.
[41] S. Pääbo,et al. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals , 2020, Nature.
[42] Barbara B. Shih,et al. Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.
[43] Q. Shu,et al. Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment , 2020, ESC heart failure.
[44] S. Kang,et al. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses , 2020, Infection, Genetics and Evolution.
[45] M. Gambardella,et al. Heterogeneity of clinical and radiological findings of COVID-19 , 2020, Postgraduate Medical Journal.
[46] S. Gregori,et al. HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives , 2020, Frontiers in Immunology.
[47] Q. Ye,et al. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19 , 2020, American journal of physiology. Gastrointestinal and liver physiology.
[48] J. Vojtková,et al. Immune Parameters and COVID-19 Infection – Associations With Clinical Severity and Disease Prognosis , 2020, Frontiers in Cellular and Infection Microbiology.
[49] J. Erdmann,et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.
[50] P. Kuppen,et al. HLA-G: A New Immune Checkpoint in Cancer? , 2020, International journal of molecular sciences.
[51] A. Basu,et al. Faculty Opinions recommendation of Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[52] Q. Ye,et al. Hepatic complications of COVID‐19 and its treatment , 2020, Journal of medical virology.
[53] C. Pellegrini,et al. NKG2A and COVID-19: another brick in the wall , 2020, Cellular & Molecular Immunology.
[54] R. Bruno,et al. Unique immunological profile in patients with COVID-19 , 2020, Cellular & Molecular Immunology.
[55] Philippe P. Pébaÿ,et al. COVID-19: beta-thalassemia subjects immunised? , 2020, Medical Hypotheses.
[56] Q. Ye,et al. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.
[57] Q. Shu,et al. Epidemiological analysis of COVID‐19 and practical experience from China , 2020, Journal of medical virology.
[58] E. Holmes,et al. A new coronavirus associated with human respiratory disease in China , 2020, Nature.
[59] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[60] E. Holmes,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.
[61] N. Messina,et al. The impact of vaccines on heterologous adaptive immunity. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[62] E. Donadi,et al. Genetic association between HLA-G 14-bp polymorphism and diseases: A systematic review and meta-analysis. , 2018, Human immunology.
[63] Edith Jasny,et al. New Vaccine Technologies to Combat Outbreak Situations , 2018, Front. Immunol..
[64] D. Hong,et al. Meta-analysis of correlationship between HLA-G 3′UTR 14-bp Ins/Del polymorphism and virus susceptibility , 2018, Medicine.
[65] T. Hviid,et al. Next‐generation sequencing of HLA‐G based on long‐range polymerase chain reaction , 2018, HLA.
[66] Jon Cohen. Far from over. , 2018, Science.
[67] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[68] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[69] E. Donadi,et al. Haplotypes of the HLA-G 3’ Untranslated Region Respond to Endogenous Factors of HLA-G+ and HLA-G- Cell Lines Differentially , 2017, PloS one.
[70] Lisa E. Gralinski,et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence , 2015, Nature Medicine.
[71] A. Sabbagh,et al. Insights into HLA-G Genetics Provided by Worldwide Haplotype Diversity , 2014, Front. Immunol..
[72] U. d’Alessandro,et al. The prevalence of glucose-6-phosphate dehydrogenase deficiency in Gambian school children , 2014, Malaria Journal.
[73] S. Agaugué,et al. Binding of HLA-G to ITIM-Bearing Ig-like Transcript 2 Receptor Suppresses B Cell Responses , 2014, The Journal of Immunology.
[74] Eduardo A. Donadi,et al. Polymorphic Sites at the 3’ Untranslated Region of the HLA-G Gene Are Associated with Differential hla-g Soluble Levels in the Brazilian and French Population , 2013, PloS one.
[75] Christian Drosten,et al. Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group , 2013, Journal of Virology.
[76] P. Marik,et al. Narrative Review , 2012, Journal of intensive care medicine.
[77] Jyothi Jayaraman,et al. Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors , 2012, Genome research.
[78] F. Weber,et al. Extracellular 2′-5′ Oligoadenylate Synthetase Stimulates RNase L-Independent Antiviral Activity: a Novel Mechanism of Virus-Induced Innate Immunity , 2010, Journal of Virology.
[79] E. Donadi,et al. The genetic structure of 3′untranslated region of the HLA-G gene: polymorphisms and haplotypes , 2010, Genes and Immunity.
[80] E. Capoluongo,et al. Glucose‐6‐phosphate dehydrogenase laboratory assay: How, when, and why? , 2009, IUBMB life.
[81] C. Vilches,et al. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. , 2007, Tissue antigens.
[82] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[83] O. Christiansen,et al. HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms , 2004, Immunogenetics.
[84] A. Cariou,et al. Coronavirus 229E-Related Pneumonia in Immunocompromised Patients , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[85] J. R. Lapa e Silva,et al. Another brick in the wall. , 2002, Sao Paulo medical journal = Revista paulista de medicina.
[86] J. Dausset,et al. An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[87] D. Geraghty,et al. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[88] Y. Azuma,et al. [Long-term results of short course chemotherapy of pulmonary tuberculosis. Second study-B: results at 6 years after the end of 4-9 month chemotherapy of pulmonary tuberculosis]. , 1987, Kekkaku : [Tuberculosis].
[89] A. Cao,et al. Beta thalassaemia mutations in Sardinians: implications for prenatal diagnosis. , 1987, Journal of medical genetics.
[90] W. Kruskal,et al. Use of Ranks in One-Criterion Variance Analysis , 1952 .
[91] F. Meloni,et al. Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection , 2021, PloS one.
[92] E. Gianicolo,et al. [Sex/gender differences in COVID-19 lethality: what the data say, and do not say]. , 2020, Epidemiologia & Prevenzione.
[93] J. Sterne,et al. Essential Medical Statistics , 2003 .
[94] R. B. Heisch. How, what and why. , 1963, East African medical journal.